Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. - Szepietowski JC; Reich A; Feldman SR; Pulka G; Mekokishvili L; Tsiskarishvili N; Svarca I; Poder A; Singh G; Deodhar S; Kumar K; Marwah A; et al. (Expert opinion on biological therapy, 2025)